Comparative Pharmacology
Head-to-head clinical analysis: BROMOCRIPTINE MESYLATE versus DOSTINEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BROMOCRIPTINE MESYLATE versus DOSTINEX.
BROMOCRIPTINE MESYLATE vs DOSTINEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bromocriptine mesylate is a dopamine D2 receptor agonist that also exhibits partial agonist activity at D1 receptors. By stimulating dopamine receptors in the tuberoinfundibular pathway, it inhibits prolactin secretion from the anterior pituitary. It also activates postsynaptic dopamine receptors in the striatum, improving motor function in Parkinson disease. Additionally, it has been shown to improve glycemic control in type 2 diabetes by modulating central dopaminergic tone and reducing hepatic glucose production.
Cabergoline is a long-acting dopamine D2 receptor agonist that inhibits prolactin secretion by binding to D2 receptors on lactotroph cells in the anterior pituitary.
Oral: 1.25-2.5 mg twice daily, increased gradually as tolerated. Maximum 100 mg/day. Also used intravaginally for hyperprolactinemia (2.5 mg once daily).
0.25 mg orally twice weekly, with a minimum of 2 days between doses; may increase by 0.25 mg twice weekly every 4 weeks up to a maximum of 1 mg twice weekly.
None Documented
None Documented
Terminal elimination half-life is approximately 6-8 hours in healthy individuals, but may be prolonged to 12-14 hours in patients with hepatic impairment or in the elderly.
The terminal elimination half-life is 63–69 hours in healthy volunteers and 79–115 hours in patients with hyperprolactinemia, allowing once- or twice-weekly dosing. The long half-life reflects slow dissociation from D2 receptors and enterohepatic recirculation.
Primarily hepatic metabolism with 85-90% fecal excretion via bile; <5% renal excretion as unchanged drug and metabolites.
Cabergoline is extensively metabolized in the liver, primarily via CYP3A4. Elimination is predominantly fecal (60%) and renal (20%) as metabolites, with <4% as unchanged drug. Biliary excretion contributes to fecal elimination.
Category A/B
Category C
Dopamine Agonist
Dopamine Agonist